Compare IDEXX Laboratories, Inc. (IDXX) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Lockheed Martin Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Lockheed Martin Corporation trades at $606.57 (market cap $137.96B). The key difference: Lockheed Martin Corporation is far larger — about 3× IDEXX Laboratories, Inc.'s market cap, and Lockheed Martin Corporation pays a 2.31% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | LMT | |
|---|---|---|
Market Cap | $46.22B | $137.96B |
Sector | Health | Industrials |
52-Week High | $766.68 | $676.70 |
52-Week Low | $526.44 | $431.56 |
Enterprise Value | $47.12B | $154.71B |
Dividend Yield | — | 2.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Lockheed Martin (LMT) trades at $606.71, up 0.59% on the day, near its consensus price target of $608. The stock shows bullish technical momentum with strong moving average signals and is supported by a record $230.4 billion backlog as of Q2 2026 (Seeking Alpha, August 4, 2026). Recent earnings beat expectations in Q2 2026 with EPS of $7.94 versus $7.22 estimated, though Q4 2025 and Q1 2026 results missed. The company maintains robust cash flow, with 2025 operating cash flow at $8.56 billion, and benefits from major defense contracts, including a $53.9 billion Patriot missile order (The Motley Fool, August 11, 2026).
Outlook is positive due to strong defense spending trends and execution, but risks include earnings volatility and debt levels. The stock offers steady dividends and growth potential, with analyst consensus leaning bullish. Key risks involve reliance on government contracts and macroeconomic pressures on defense budgets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
